Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalfampridine Combined With Physical Therapy for Mobility Impairment in People With Multiple Sclerosis
NCT06136728Phase 3Recruiting
- Sponsor
- MGH Institute of Health Professions
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dalfampridine in multiple sclerosis (MS), sponsored by MGH Institute of Health Professions. Started Jun 2024; status: recruiting.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06136728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06136728.